Flu Spike Protein

Lab Reagents

Human IgG antibody Laboratories manufactures the flu spike protein reagents distributed by Genprice. The Flu Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Flu products are available in stock. Specificity: Flu Category: Spike Group: Protein

Protein information

SARS-CoV Spike Protein

abx060655-1mg 1 mg
EUR 1692

SARS-CoV spike protein Antibody

abx023139-100ug 100 ug
EUR 857

SARS-CoV spike protein Antibody

abx023143-100ug 100 ug
EUR 857

SARS Spike RBD Recombinant Protein

10-211 0.1 mg
EUR 542.75
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

MERS Spike S1 Recombinant protein

39-102 0.1 mg
EUR 464
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis.

SARS Spike Antibody

24216-100ul 100ul
EUR 390

SARS Spike Antibody

24217-100ul 100ul
EUR 390

SARS Spike Antibody

24218-100ul 100ul
EUR 390

SARS Spike Antibody

24219-100ul 100ul
EUR 390

SARS Spike Antibody

24318-100ul 100ul
EUR 390

SARS Spike Antibody

20-abx137184
  • EUR 1052.00
  • EUR 1539.00
  • EUR 1720.00
  • 100 ug
  • 200 ug
  • 300 µg

SARS Spike Antibody

20-abx137200
  • EUR 1177.00
  • EUR 1887.00
  • EUR 2221.00
  • 100 ug
  • 200 ug
  • 300 µg

Spike Glycoprotein Antibody

20-abx300551
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

SARS Spike Peptide

3219P 0.05 mg
EUR 164.75
Description: (NT) SARS Spike peptide

SARS Spike Peptide

3525P 0.05 mg
EUR 164.75
Description: (CT) SARS Spike peptide

Swine-Origin and Seasonal Flu H1N1 Protein Detection Set

PSI-1829 1 Set
EUR 1188.5
Description: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin (4). The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups (5). Antibodies #5235 and 5239 are specific for the seasonal H1N1 influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the swine-origin H1N1 influenza (A/California/14/2009 (H1N1)). Similarly, antibodies #5237 and #5241 are specific for the swine-origin H1N1 influenza Hemagglutinin and will not recognize the seasonal H1N1 Hemagglutinin (A/Brisbane/59/2007 (H1N1). The Neuraminidase antibodies #5247 and #5249 are specific for seasonal and swine-origin H1N1 influenza Neuraminidase, respectively.;;For images please see PDF data sheet

Human Influenza viruses IgG(FLU)ELISA Kit

GA-E1783HM-48T 48T
EUR 289